Biomedical Science and Clinical Research(BSCR)
ISSN: 2835-7914 | DOI: 10.33140/BSCR
Impact Factor: 1.7
Post-COVID Hypercoagulability: Implications for Perioperative Anticoagulation and Thromboembolism Prevention in Surgical Patients
Abstract
Brendan Jones
Background: SARS-CoV-2 infection induces a persistent prothrombotic state involving endothelial dysfunction, elevated coagulation markers, and systemic inflammation. This hypercoagulable state can persist for weeks to months post-infection, posing unique challenges for perioperative thromboembolism risk assessment and anticoagulation management.
Objectiv: This review synthesizes emerging evidence on post-COVID hypercoagulability and its implications for perioperative anticoagulation and thromboprophylaxis in surgical patients.
Methods: A narrative review of clinical trials, observational studies, guidelines, and meta- analyses retrieved from PubMed was conducted, focusing on perioperative thrombotic risk in post-COVID patients.
Results: Persistent endothelial dysfunction, platelet activation, and elevated D-dimer levels contribute to sustained thrombotic risk post-COVID. Incidence of venous thromboembolism (VTE) post-discharge ranges from 0.6% to 2.5%. Extended thromboprophylaxis may reduce VTE in high-risk surgical patients, but bleeding risks remain significant.
Conclusion: Individualized perioperative risk assessment, consideration of biomarker-guided prophylaxis, and selective use of extended anticoagulation are essential until more robust surgical data emerge.